1. Home
  2. HBIO vs INAB Comparison

HBIO vs INAB Comparison

Compare HBIO & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$0.60

Market Cap

22.1M

Sector

Industrials

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.72

Market Cap

22.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBIO
INAB
Founded
1901
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.1M
22.9M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
HBIO
INAB
Price
$0.60
$1.72
Analyst Decision
Buy
Strong Buy
Analyst Count
3
2
Target Price
$2.50
$108.00
AVG Volume (30 Days)
537.0K
64.2K
Earning Date
03-12-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$87,371,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$1.17
52 Week High
$1.43
$10.04

Technical Indicators

Market Signals
Indicator
HBIO
INAB
Relative Strength Index (RSI) 54.16 37.14
Support Level $0.53 $1.70
Resistance Level $0.65 $2.05
Average True Range (ATR) 0.04 0.16
MACD 0.01 -0.04
Stochastic Oscillator 69.66 6.38

Price Performance

Historical Comparison
HBIO
INAB

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Share on Social Networks: